Press Releases

Date Title and Summary View
Toggle Summary Revance Announces China Market License Agreement with Fosun Pharma for RT002
– Upfront payment of $30 million , plus potential milestone payment and tiered royalties on future sales – NEWARK, Calif. --(BUSINESS WIRE)--Dec. 4, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and
View HTML
Toggle Summary Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
– In SAKURA 3, RT002 was well-tolerated across over 3,800 treatments in glabellar (frown) lines – – The median time to return to baseline glabellar line severity was 28 weeks – – RT002 represents the first long-acting neuromodulator, allowing for two or fewer treatments per year – – Revance
View HTML
Toggle Summary Revance to Participate in Upcoming Investor Conferences
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 20, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor
View HTML
Toggle Summary Revance to Participate in the Credit Suisse Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 7, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare
View HTML
Toggle Summary Revance Releases Third Quarter 2018 Results
- Chief Financial Officer Toby Schilke and Interim Head of Commercial - Aesthetics & Therapeutics Dustin Sjuts to assume roles on November 5 - NEWARK, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation
View HTML
Toggle Summary Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
-Conference Call Scheduled for Thursday, November 1, 2018 at 4:30pm ET - NEWARK, Calif. --(BUSINESS WIRE)--Oct. 18, 2018-- Revance Therapeutics, Inc.  (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the
View HTML
Toggle Summary Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer
NEWARK, Calif. --(BUSINESS WIRE)--Oct. 11, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it has strengthened its leadership team with the appointment of Tobin C.
View HTML
Toggle Summary Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Sep. 24, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare
View HTML
Toggle Summary Revance Receives Great Place to Work Certification
NEWARK, Calif. --(BUSINESS WIRE)--Sep. 20, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company was certified as a great workplace this month by the independent
View HTML
Toggle Summary Revance Releases Second Quarter 2018 Results
NEWARK, Calif. --(BUSINESS WIRE)--Aug. 2, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2018 .
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools